Seek

Roderick Bransgrove's original business experience was gained in the pharmaceutical industry, having worked for Schering Chemicals Limited (the UK subsidiary of Schering AG) for 15 years. Rod joined Schering in 1972 and completed a career path through Marketing and Sales Management into General Management. In 1986, he founded Imperial Pharmaceutical Services Limited which merged with Shire Pharmaceuticals Group plc ("Shire") in 1995. From 1995-1998 Rod was a Non-Executive Director of Shire. He is also Chairman of Entertainment Rights plc., which is listed on the London Stock Exchange, a company specialising in the exploitation of intellectual property rights and children's television characters. Rod also became Chairman of Rose Bowl plc., which incorporated Hampshire Cricket Limited in October 2000. Other Directorships include England and Wales Cricket Board.

John Hardy has a scientific background and a career in film finance and the advisory area of Investment Banks, ultimately being a shareholder in a listed Investment Bank, which he was involved in creating. John currently is involved in the provision of complex funding with particular emphasis on structured finance.

Feroze Janmohamed has a pharmaceutical background and currently co invests with Roderick Bransgrove in a number of different investments including medical scientific entities.

Kim Duncan has 20 years’ experience in the investment business. After graduating from Yale University with a BSc in Electrical Engineering, Kim began his career as a trader at Goldman Sachs in 1987. From there, he went on to Nomura, Credit Suisse and Mizuho, leading teams conducting principal investment activities in which the firms' capital was invested directly for their own account. Major transactions include the acquisitions of Inntrepreneur Pub chain, Ange l Trains, AT&T Capital, and Stenvalvet AB. Kim has extensive experience in structured finance, leveraged finance and credit derivatives trading. As well as SEEK, Kim sits on the boards of various early stage ventures including Curemark LLP, Pharmajet Inc., as well as Spatial View Inc., Flying Aces Limited, and Ignite Gaming Technologies.

Gregory Stoloff founded SEEK – formerly known as PepTcell - in 2004 after a distinguished career in investment banking spanning 20 years, working in a broad range of institutions including Deutsche Bank and UBS. He initially concentrated on corporate finance and was involved in numerous mergers and acquisitions and structured finance with an emphasis on the healthcare industry, including mergers by GlaxoSmithKline, Aventis and Pfizer. Gregory then moved on to concentrate on project finance and was involved in financings for major pharmaceutical companies such as Roche, Merck and Novartis and across various other sectors. Gregory also has a wealth of experience in advising and working with medical research companies.

Gregory is a qualified Chartered Accountant and has spent many years researching scientific medical issues, specifically related to the immune system. He has also been involved in several publications, recounting research in the peptide space and is listed as an inventor in numerous patents for cancer, HIV, mosquito-borne diseases and influenza.

Gregory has been instrumental in the development of the concepts pursued by SEEK and has been the driving force behind the Group’s continued growth and diversification.

James Synge has been with SEEK since its founding in 2004 and was instrumental in its formation. James started his career over 25 years ago with a Chartered Accounting firm in Sydney, Australia. Following his time as a Chartered Accountant, he worked in investment banking and spent 15 years holding senior positions in Bankers Trust, Deutsche Bank and UBS in Australia, Germany and Switzerland. During this time, he spent time working in the corporate divisions, concentrating on taxation and regulatory matters and then moved into the international structured finance groups in all three organisations. While in investment banking, James was involved in numerous transactions across a wide range of industries including Media, Infrastructure and Finance.

Since 2001, James has held a number of pivotal investment and management roles in companies in a wide range of sectors including Biotechnology, Funds Management, Internet Service Companies and Gaming enterprises. James is an experienced private investor who lends both financial and management experience to a broad range of companies.